Shanghai Rightongene Biotechnology Co. Ltd. A
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of molecular diagnosis of infectious diseases in China. The company offers self-operated reagents, purchased preparations, scientific research services, and testing services for blood diseases, solid tumors, infectious diseases and lymphoma. Shanghai Rightongene Biotechnology Co., Ltd. was f… Read more
Shanghai Rightongene Biotechnology Co. Ltd. A (688217) - Net Assets
Latest net assets as of June 2025: CN¥919.52 Million CNY
Based on the latest financial reports, Shanghai Rightongene Biotechnology Co. Ltd. A (688217) has net assets worth CN¥919.52 Million CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥960.48 Million) and total liabilities (CN¥40.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥919.52 Million |
| % of Total Assets | 95.74% |
| Annual Growth Rate | 8.65% |
| 5-Year Change | 39.11% |
| 10-Year Change | N/A |
| Growth Volatility | 14.01 |
Shanghai Rightongene Biotechnology Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how Shanghai Rightongene Biotechnology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Rightongene Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual net assets of Shanghai Rightongene Biotechnology Co. Ltd. A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥920.64 Million | -4.86% |
| 2023-12-31 | CN¥967.68 Million | -0.39% |
| 2022-12-31 | CN¥971.42 Million | +8.34% |
| 2021-12-31 | CN¥896.67 Million | +35.49% |
| 2020-12-31 | CN¥661.79 Million | +8.85% |
| 2019-12-31 | CN¥607.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Rightongene Biotechnology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 366.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥138.26 Million | 15.21% |
| Other Components | CN¥770.99 Million | 84.79% |
| Total Equity | CN¥909.26 Million | 100.00% |
Shanghai Rightongene Biotechnology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai Rightongene Biotechnology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CN EVERBRIGHT WATER HD 1
F:BIU2
|
$128.27 Million |
|
Biofarm Bucure
RO:BIO
|
$128.28 Million |
|
Q-Free ASA
PINK:QFREF
|
$128.29 Million |
|
VESTUM AB AK
F:W0S
|
$128.33 Million |
|
Sinphar Pharmaceutical Co Ltd
TW:1734
|
$128.24 Million |
|
Dongbu Corp
KO:005965
|
$128.16 Million |
|
Prime US REIT
OTCGREY:KBSUF
|
$128.15 Million |
|
RocKontrol Technology Group Co Ltd
SHG:688051
|
$128.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Rightongene Biotechnology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 945,776,280 to 909,256,094, a change of -36,520,186 (-3.9%).
- Net loss of 15,764,502 reduced equity.
- Dividend payments of 619,878 reduced retained earnings.
- Other factors decreased equity by 20,135,806.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-15.76 Million | -1.73% |
| Dividends Paid | CN¥619.88K | -0.07% |
| Other Changes | CN¥-20.14 Million | -2.21% |
| Total Change | CN¥- | -3.86% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Rightongene Biotechnology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.05x to 1.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥14.59 | CN¥29.84 | x |
| 2020-12-31 | CN¥15.52 | CN¥29.84 | x |
| 2021-12-31 | CN¥15.99 | CN¥29.84 | x |
| 2022-12-31 | CN¥16.86 | CN¥29.84 | x |
| 2023-12-31 | CN¥16.93 | CN¥29.84 | x |
| 2024-12-31 | CN¥16.28 | CN¥29.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Rightongene Biotechnology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.51%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.08x
- Recent ROE (-1.73%) is below the historical average (3.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 5.91% | 14.07% | 0.39x | 1.08x | CN¥-24.85 Million |
| 2020 | 5.99% | 13.59% | 0.39x | 1.12x | CN¥-25.96 Million |
| 2021 | 5.33% | 16.27% | 0.31x | 1.07x | CN¥-41.55 Million |
| 2022 | 4.32% | 9.54% | 0.39x | 1.16x | CN¥-53.22 Million |
| 2023 | 0.84% | 3.07% | 0.25x | 1.10x | CN¥-86.65 Million |
| 2024 | -1.73% | -6.51% | 0.25x | 1.08x | CN¥-106.69 Million |
Industry Comparison
This section compares Shanghai Rightongene Biotechnology Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,722,009,584
- Average return on equity (ROE) among peers: 7.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Rightongene Biotechnology Co. Ltd. A (688217) | CN¥919.52 Million | 5.91% | 0.04x | $128.25 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $183.33 Million | -11.06% | 0.92x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.03 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $248.75 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $860.44 Million |
| Hualan Biological EngineeringInc (002007) | $4.84 Billion | 16.95% | 0.08x | $2.01 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.20 Billion | 4.62% | 0.66x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.81 Billion | 11.12% | 0.67x | $414.37 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.77 Billion | 15.42% | 0.67x | $347.52 Million |